目的 探討不同劑量辛伐他汀治療慢性阻塞性肺疾?。–OPD）的療效、安全性及對(duì)肺功能的影響。方法 選取2015年7月—2016年1月于榆林市第二醫(yī)院接受治療的COPD患者192例作為研究對(duì)象，采用隨機(jī)數(shù)字表法分為A、B兩組，各96例。A組患者使用辛伐他汀劑量為40 mg/d，B組患者使用劑量為20 mg/d。兩組均進(jìn)行為期6個(gè)月的治療。比較兩組患者臨床療效、肺功能[主要指標(biāo)包括第一秒用力呼氣容積（FEV1）、第一秒用力呼氣容積占預(yù)計(jì)值百分比（FEV1%）、用力肺活量（FVC）]、生活質(zhì)量及安全性。結(jié)果 A組治療1個(gè)月時(shí)總有效率（82.29%）與B組（70.83%）相比差異不明顯；治療3個(gè)月（89.85% vs 77.08%）及6個(gè)月時(shí)（93.75% vs 84.38%）均明顯高于B組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療1個(gè)月時(shí)兩組肺功能各指標(biāo)差異不明顯，治療3個(gè)月及6個(gè)月時(shí)A組各指標(biāo)均明顯優(yōu)于B組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后兩組生活質(zhì)量均得到明顯好轉(zhuǎn)，A組患者生活質(zhì)量明顯優(yōu)于B組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。兩組患者用藥安全性比較無顯著差異。結(jié)論 大劑量辛伐他汀治療COPD療效及安全性良好，可顯著改善肺功能并提高患者生活質(zhì)量，值得臨床推廣應(yīng)用。

Objective To explore the clinical effect, safety and influence on pulmonary function of different doses of simvastatin in treatment of COPD.Methods Totally 192 COPD patients accepted in The Second Hospital of Yulin from July 2015 to January 2016 were selected and randomly divided into groups A and B with 96 cases in each group. Patients in group A were given 40 mg/d simvastatin, and patients in group B were given 20 mg/d simvastatin. Then the clinical effect, pulmonary function, life quality and safety of two groups were compared.Results The total effective rates after 1 month treatment of group A and group B were 82.29% and 70.83% respectively, which had no difference between two groups. The total effective rates of group A after 3 months treatment (89.95% vs 77.08%) and 6 months treatment (93.75% vs 84.38%) were higher than that of group B, and the differences were significantly (P<0.05). The indexes of pulmonary function after 1 month treatment of two groups had no difference. The indexes of pulmonary function after 3 months and 6 months of treatment of group A were obviously better than those of group B, and the differences were significantly (P<0.05). The life quality of group A was better than group B, and the differences were significantly (P<0.05). The safety between two groups had no difference.Conclusion Simvastatin (40 mg/d) has good effect and safety in the treatment of COPD, which can improve the lung function and life quality and is worthy of clinical applications.